![Nils Martin Malmsten](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Nils Martin Malmsten
Corporate Officer/Principal presso University of Uppsala
Posizioni attive di Nils Martin Malmsten
Società | Posizione | Inizio | Fine |
---|---|---|---|
University of Uppsala | Corporate Officer/Principal | - | - |
Storia della carriera di Nils Martin Malmsten
Precedenti posizioni note di Nils Martin Malmsten
Società | Posizione | Inizio | Fine |
---|---|---|---|
Sista versen 26366 AB
![]() Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden. | Direttore/Membro del Consiglio | 15/02/2010 | - |
Presidente | 15/02/2010 | 15/02/2010 | |
Fondatore | 15/02/2010 | - | |
Astra Arcus AB | Corporate Officer/Principal | - | - |
The Royal Society of Chemistry
![]() The Royal Society of Chemistry Miscellaneous Commercial ServicesCommercial Services The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists. | Corporate Officer/Principal | - | - |
DermaGen AB
![]() DermaGen AB Pharmaceuticals: MajorHealth Technology DermaGen AB develops drugs and medical devices. It focuses on the development of topically applied products for the prevention and treatment of bacterial and fungal skin infections. The company was founded on February 2, 2004 and is headquartered in Solna, Sweden. | Direttore/Membro del Consiglio | 01/05/2004 | - |
Fondatore | 17/07/2009 | - |
Statistiche
Distribuzione geografica
Svezia | 5 |
Regno Unito | 2 |
Posizioni
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Founder | 2 |
Settori
Health Technology | 3 |
Consumer Services | 2 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
DermaGen AB
![]() DermaGen AB Pharmaceuticals: MajorHealth Technology DermaGen AB develops drugs and medical devices. It focuses on the development of topically applied products for the prevention and treatment of bacterial and fungal skin infections. The company was founded on February 2, 2004 and is headquartered in Solna, Sweden. | Health Technology |
Astra Arcus AB | |
The Royal Society of Chemistry
![]() The Royal Society of Chemistry Miscellaneous Commercial ServicesCommercial Services The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists. | Commercial Services |
Sista versen 26366 AB
![]() Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden. | Health Technology |
- Borsa valori
- Insiders
- Nils Martin Malmsten
- Esperienza